3) D Simon, MA Charles, K Nahoul, G Orssaud, J Kremski, V Hully, E Joubert, L Papoz, E Eschwege. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The telecom study. Journal of Clinical Endocrinology and Metabolism 82:2(FEB 1997):682-685. Some doctors give the low dose injections of 25 mg of testosterone cypionate or enanthate every 2 weeks. The treatment for men who have almost no testosterone is 10 times that dosage. A normal male produces the equivalent of 100 mg of testosterone (enanthate) each week.
DEPO - Testosterone (testosterone cypionate injection) is an androgen indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone including, 1) Primary hypogonadism ( congenital or acquired ) - testicular failure due to cryptorchidism , bilateral torsion, orchitis , vanishing testis syndrome, or orchidectomy; and 2) Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary -hypothalamic injury from tumors, trauma , or radiation . Common side effects of DEPO -Testosterone include:
Other side effects include increased risk of heart problems in older men with poor mobility, according to a 2009 study at Boston Medical Center. A 2017 study published in JAMA found that treatments increase coronary artery plaque volume. Additionally, the Food and Drug Administration (FDA) requires manufactures to include a notice on the labeling that states taking testosterone treatments can lead to possible increased risk of heart attacks and strokes. The FDA recommends that patients using testosterone should seek medical attention right away if they have these symptoms: